Prospective study of hyperglycemia and cancer risk: Response to Stattin et al. [19]

Diabetes Care

Volumn 30, Issue 7, 2007, Pages

  Bowker, Samantha L ^a,b   Johnson, Jeffrey A ^a,b,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b INSTITUTE OF HEALTH ECONOMICS   (Canada)

^c NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

CANCER RISK; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN TREATMENT; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS;

DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERGLYCEMIA; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; MALE; NEOPLASMS; RISK;

EID: 34447122461     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc07-0544     Document Type: Letter

References (7)

1. Stattin P, Bjor O, Ferrari P, Lukanova A, Lenner P, Lindahl B, Hallmans G, Kaaks R: Prospective study of hyperglycemia and cancer risk. Diabetes Care 30:561-567, 2007
2. Giovannucci E: Insulin and colon cancer. Cancer Causes Control 6:164-179, 1995
3. Rosenfeld RG: Insulin-like growth factors and the basis of growth. N Engl J Med 349:218-216, 2003
4. Bowker SL, Majumdar SR, Veugelers P, Johnson JA: Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29:254-258, 2006
5. Evans JMM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD: Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304-1305, 2005
6. Van der Burg BB, Rutterman GR, Blankenstein MA, et al: Mitogenic stimulation of human breast cancer cells in a growth-defined medium: Synergistic action of insulin and estrogen. J Cell Physiol 134:101-108, 1988
7. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M: Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66:10269-73, 2006